$100 Billion of US and European Pharmaceutical Company Revenues Threatened by Generic Drugs Forecasts URCH Publishing.Generics Grow to Capture 14% of the Global Healthcare Market LONDON -- Over $100 billion in revenue of major branded drugs is under threat from new generic products as patents expire over the next five years. The most dramatic change in this period will arise in the period 2010-12 as the patents covering Pfizer's best-seller Lipitor expire, predicts a new report 'Generic Competition 2007 to 2011 - The impact of patent expiries on sales of major drugs'. The report, published by business information supplier URCH Publishing, notes that the period 2007-11 will see the expiration EXPIRATION. Cessation; end. As, the expiration of, a lease, of a contract, or statute. 2. In general, the expiration of a contract puts an end to all the engagements of the parties, except to those which arise from the non- fulfillment of obligations created of patent protection for an average of ten drugs a year in the US. As 2005 saw a decline in the number of NCEs approved down to 18 from 23 in 2004, there is clear evidence that the loss of revenue from patent-protected drugs will impact upon the growth of the industry when so few new drugs are reaching the market. "There is a considerable difference between the top 20 pharmaceutical companies in both the number of products and the amount of revenues under threat from the potential introduction of generics," said Dr Peter Norman Peter George Norman (June 15, 1942 – October 3, 2006) was an Australian track star best known for winning the silver medal in the 200 metres at the 1968 Summer Olympics in Mexico City. His time of 20.06 seconds still stands as the Australian 200 metre record[1]. , the report's author. "Neither Amgen, which currently markets only biological products, nor Merck KGaA This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. , whose portfolio is primarily mature products, face any threat from generic competition, while Roche, Bayer-Schering, Abbott and Schering-Plough face limited threats to their revenues," added Dr Norman. The most severely affected companies are Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were , Takeda, AstraZeneca and Eli Lilly Eli Lilly can refer to:
In 2005 global sales of generic products were estimated to be $65 billion, accounting for 14% of the global healthcare market. The five year period to 2011 could see $20 billion of additional revenues generated by the generics companies, significantly enhancing their growth prospects. Sandoz and Teva could be the beneficiaries of this growth, says the report. The 130 page 'Competition 2007 to 2011' is relased on 26th Febraury. More information about the report can be found at http://www.urchpublishing.com/publications/general/generic_ competition_2011_00.html (Due to the length of this URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. , it may be necessary to copy and paste To copy files from one location to another or to copy text and images from one document to another. All modern operating systems and applications have a copy and paste capability that is typically selected from an Edit menu. See cut and paste and Win Copy between windows. this hyperlink into your Internet browser's URL address field.) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion